Moolec Science (MLECW) Asset Utilization Ratio (2023 - 2024)
Moolec Science (MLECW) posted Asset Utilization Ratio of 0.25 for Q4 2024, up 2111.44% sequentially from 0.01 in Q3 2024, and up 118.73% YoY from 0.11 in Q1 2024.
Moolec Science (MLECW) Asset Utilization Ratio (2023 - 2024) Analysis & Trends
Moolec Science has reported Asset Utilization Ratio for 2 years, with the latest figure at 0.25 in Q4 2024.
- Quarterly Asset Utilization Ratio rose 118.73% year-over-year to 0.25 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.25 (up 118.73% YoY) and the FY2024 annual result came in at 0.01, down 81.02% from the prior year.
- Asset Utilization Ratio advanced to 0.25 in Q4 2024 per MLECW's latest filing, from 0.01 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.25 in Q4 2024 and troughed at 1.98 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.13 |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 0.25 |
| Sep 30, 2024 | 0.01 |
| Jun 30, 2024 | 0.01 |
| Mar 31, 2024 | -1.12 |
| Dec 31, 2023 | -1.31 |
| Sep 30, 2023 | -1.24 |
| Jun 30, 2023 | -1.98 |
| Mar 31, 2023 | 0.00 |